(To see other currencies, click on price)
MORE ABOUT THIS BOOK
Main description:
The three years since our last conference in San Francisco have again seen a dramatic expansion of the number of antivirals either licensed or in the late stages of clinical trials. d4T is now licensed for HIV infection, famciclovir and the oral pro-drug of acyclovir, valacyclovir, are now licensed for VZV infections in some countries. Moreover. oral ganciclovir, cidofovir, and sorivudine are not far behind. Clinical trials with the second-site reverse transcriptase inhibitors and the protease inhibitors for HlV infection are proceeding rapidly and on a broad scale, and the preliminary results would suggest that several of these classes of drugs will be licensed as well. Despite this optimism, however, there is increasing evidence that antiviral-resistant strains of pathogenic viruses will be a significant problem, perhaps especially with therapy of HIV infection, and there remains a desperate need for improved drugs (with either improved efficacy or decreased toxicity, or both) for CMV and HIV infections. This book is the edited proceedings of the Fourth Triennial Conference on Antiviral Chemotherapy, held in San Francisco, in November 1994. The conference was sponsored by the University of California, San Francisco, and co-sponsored by the International Society for Antiviral Research (ISAR), the Macfarlane Burnet Centre for Medical Research in Melbourne, Australia, and the Australian National Centre for HIV Virology Research. The conference had been organized to present an overview of the field of antiviral chemotherapy.
Contents:
Management of Genital Herpes; G.J. Mertz Subclinical Shedding of HSV: Its Potential for Reduction by Antiviral Therapy; L. Corey, et al. Famciclovir: Efficacy in Zoster and Issues in the Assessment of Pain; R.J. Boon, D.R.J. Griffin Valacyclovir Hcl (Valtrex (R)): AnAcyclovir Prodrug with Improved Pharmacokinetics and Better Efficacy for Treatment of Zoster; M.L. Smiley; et al. Sorivudine: A Potent Inhibitor of Varicella Zoster Virus Replication; R.J.Whitley Summary of Panel Discussion about Antiviral Therapy for Zoster; A.M. Arvin, et al. Antiviral Drug Resistance in Herpes Simplex Virus; D.M. Coen Treatment of Acyclovirresistant Herpes Simplex and Varicella Zoster Virus Infections; S. Safrin Therapeutic Immunization for Recurrent Herpes Simplex Virus Infections; R. McKenzie, S.E. Straus Current Management of Cytomegalovirus Retinitis in AIDS Update on Ganciclovir and Foscarnet for CMV Infections; M.A. Jacobson A Preclinical and Clinical Overview of the Nucleotidebased Antiviral Agent Cidofovir (HPMPC); J.P. Lalezari, et al. Prophylaxis and Treatment of CMV Infections in Transplantation; J.A. Zaia Cytomegalovirus: Genetics of Drug Resistance; K.K.Biron Immunotherapy of CMV Infections; D.P. Paar, R.B. Pollard Hantavirus Infections in the United States: Diagnosis and Treatment; G. Mertz, L. Chapman Management of Respiratory Syncytial Virus Infections; J. Mills Update on Therapy of Influenza and Rhinovirus Infections; E. Arruda, F.G. Hayden Therapy for Chronic Hepatitis B Infection; N.A. Terrault, T.L.Wright Treatment of Chronic Hepatitis C Virus Infection: A Clinical and VirologicalPerspective; D.R. Gretch, et al. The Clinical Use of Didanosine J. Kahn ddC (Zalcitabine); G. Skowron Delavirdine Mesylate: A Potent Nonnucleoside HIV1 Reverse Transcriptase Inhibitor; W.W. Freimuth Clinical Experience with Nonnucleoside Reverse Transcriptase Inhibitors: L697, 661 and Nevirapine; J.M. Kilby, M.S. Saag Current Clinical Experience with Nevirapine for HIV Infection; A. Carr, D.A. Cooper Saquinavir: An HIV Proteinase Inhibitor; K. Bragman Perspectives in HIV Protease Inhibitors; J.M. Leonard 13 additional articles. Index.
PRODUCT DETAILS
Publisher: Springer (Springer-Verlag New York Inc.)
Publication date: April, 2013
Pages: 440
Weight: 694g
Availability: Available
Subcategories: Immunology, Pharmacology
From the same series
